Analysts Set Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Price Target at $779.45

03 Jan 2026, 05:06 by Jessica Moore · The Cerbat Gem

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Get Free Report) has been assigned a consensus rating of “Moderate Buy” from the twenty-seven research firms that are currently covering the stock, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, eight have issued a hold recommendation, fifteen have assigned a buy recommendation and three have given a strong buy recommendation to the company. The average 1 year target price among brokerages that have covered the stock in the last year is $779.4545.

Several equities analysts have recently weighed in on REGN shares. Hsbc Global Res raised Regeneron Pharmaceuticals to a “strong-buy” rating in a research report on Monday, November 24th. Royal Bank Of Canada boosted their price objective on shares of Regeneron Pharmaceuticals from $704.00 to $708.00 and gave the company a “sector perform” rating in a research report on Wednesday, October 29th. Cantor Fitzgerald increased their target price on shares of Regeneron Pharmaceuticals from $678.00 to $740.00 and gave the company an “overweight” rating in a research note on Wednesday, October 29th. Canaccord Genuity Group lifted their price target on shares of Regeneron Pharmaceuticals from $850.00 to $1,057.00 and gave the stock a “buy” rating in a research note on Thursday, December 4th. Finally, Morgan Stanley upped their price target on shares of Regeneron Pharmaceuticals from $767.00 to $768.00 and gave the company an “equal weight” rating in a report on Friday, December 12th.

Read Our Latest Stock Report on Regeneron Pharmaceuticals

Regeneron Pharmaceuticals Stock Up 0.6%

Shares of NASDAQ REGN opened at $776.31 on Monday. The company has a current ratio of 4.06, a quick ratio of 3.33 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals has a 12-month low of $476.49 and a 12-month high of $792.77. The firm’s 50-day moving average price is $723.10 and its 200-day moving average price is $618.39. The stock has a market capitalization of $81.59 billion, a price-to-earnings ratio of 18.59, a P/E/G ratio of 2.30 and a beta of 0.39.

Regeneron Pharmaceuticals (NASDAQ:REGN – Get Free Report) last issued its quarterly earnings data on Tuesday, October 28th. The biopharmaceutical company reported $11.83 earnings per share for the quarter, topping the consensus estimate of $9.73 by $2.10. The company had revenue of $3.75 billion for the quarter, compared to analysts’ expectations of $3.57 billion. Regeneron Pharmaceuticals had a return on equity of 13.76% and a net margin of 32.13%.The firm’s revenue for the quarter was up .9% on a year-over-year basis. During the same period in the previous year, the firm posted $12.46 earnings per share. On average, equities research analysts anticipate that Regeneron Pharmaceuticals will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Friday, December 5th. Stockholders of record on Thursday, November 20th were paid a dividend of $0.88 per share. The ex-dividend date of this dividend was Thursday, November 20th. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.5%. Regeneron Pharmaceuticals’s dividend payout ratio is currently 8.43%.

Insider Activity at Regeneron Pharmaceuticals

In related news, Director Christine A. Poon sold 6,500 shares of the firm’s stock in a transaction that occurred on Wednesday, October 29th. The stock was sold at an average price of $654.27, for a total transaction of $4,252,755.00. Following the completion of the sale, the director directly owned 2,352 shares of the company’s stock, valued at approximately $1,538,843.04. This trade represents a 73.43% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, VP Jason Pitofsky sold 431 shares of the business’s stock in a transaction on Friday, November 7th. The shares were sold at an average price of $651.43, for a total value of $280,766.33. Following the transaction, the vice president owned 4,233 shares of the company’s stock, valued at approximately $2,757,503.19. The trade was a 9.24% decrease in their position. The SEC filing for this sale provides additional information. Corporate insiders own 7.02% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the stock. CoreCap Advisors LLC boosted its position in shares of Regeneron Pharmaceuticals by 9.2% in the 3rd quarter. CoreCap Advisors LLC now owns 238 shares of the biopharmaceutical company’s stock worth $134,000 after purchasing an additional 20 shares in the last quarter. Marino Stram & Associates LLC boosted its holdings in Regeneron Pharmaceuticals by 5.3% in the second quarter. Marino Stram & Associates LLC now owns 396 shares of the biopharmaceutical company’s stock worth $208,000 after acquiring an additional 20 shares in the last quarter. Strait & Sound Wealth Management LLC grew its stake in shares of Regeneron Pharmaceuticals by 3.5% during the third quarter. Strait & Sound Wealth Management LLC now owns 628 shares of the biopharmaceutical company’s stock worth $353,000 after acquiring an additional 21 shares during the last quarter. Parkside Financial Bank & Trust increased its holdings in shares of Regeneron Pharmaceuticals by 14.8% during the third quarter. Parkside Financial Bank & Trust now owns 163 shares of the biopharmaceutical company’s stock valued at $92,000 after acquiring an additional 21 shares in the last quarter. Finally, MAI Capital Management raised its position in shares of Regeneron Pharmaceuticals by 2.1% in the 3rd quarter. MAI Capital Management now owns 1,028 shares of the biopharmaceutical company’s stock valued at $578,000 after purchasing an additional 21 shares during the last quarter. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Company Profile

(Get Free Report)

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.